Roaldi previously served as chief growth officer for UnitedHealthcare Community & State.
Value-based health provider Cityblock Health named Michael Roaldi as president.1 The company, which provides services for Medicaid and dually eligible beneficiaries, brought Roaldi onboard to lead the company as it continues to scale up its operations on a national level. Previously to joining Cityblock, Roaldi served as chief growth officer for UnitedHealthcare Community & State.
In a press release, Cityblock CEO and co-founder Dr. Toyin Ajayi said, “Cityblock has seen incredible growth over the past few years in both our existing and new markets, scaling to serve more than 100,000 members across seven states and partnering with three of the top five national Medicaid health plans. We're pleased to welcome Michael as our new President to build upon this momentum. His deep expertise and proven results in the Medicaid space will be invaluable to Cityblock's next chapter of growth and maturity."
In the same press release, Roaldi said, “I have long admired Cityblock's mission and am honored to be joining the company at a pivotal time. With the convergence of policy trends and market dynamics such as Medicare-Medicaid integration, Cityblock is well positioned to become the leading nationwide provider of tech-enabled, value-based healthcare for individuals with complex needs. I look forward to being part of this exciting next chapter."
As previously stated, Cityblock has been making moves to expand its operations across the nation. In July, the company announced a partnership with Alliance Health, a managed care organization that serves over 137,000 Medicaid-eligible members in North Carolina.2 While Cityblock had been operating in North Carolina since 2021, this partnership allowed the two companies to combine Cityblock’s medical and behavioral health care to Alliance members who had access to its behavioral health and intellectual/development disability plan.
In a press release issued at the time, Alliance Health’s chief operating officer Sean Schreiber said, “Alliance believes that Cityblock's treatment approach of providing community-based integrated primary care, behavioral health care, and attention to social supports is an ideal model to address the complex needs of our members. We have been impressed with their desire and commitment to engage and serve our population."
In the same press release, Ajayi added, “"We share North Carolina and Alliance Health's longstanding commitment to providing innovative, high-quality care to members with complex behavioral health needs. Together, and on the heels of North Carolina's groundbreaking transition to Medicaid managed care, we will deploy care to treat individuals holistically and reduce health disparities, and we look forward to delivering clinical and financial outcomes for marginalized and underserved communities throughout the state."
The NC Carolina Department of Health and Human Services director of its division of mental health, developmental disabilities and substance abuse services Kelly Crosbie also added, “Access to integrated care for people with behavioral health needs is critical to the NCDHHS priority of behavioral health and resilience. People have better outcomes when we treat the mind and body–the whole person. NCDHHS applauds Alliance and Cityblock's leadership in tailoring this innovative model to address the whole-person needs of people with behavioral and substance use disorder needs."
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
Johnson & Johnson Seeks FDA Approval for Subcutaneous Tremfya Regimen for Ulcerative Colitis
November 22nd 2024Johnson & Johnson has submitted a supplemental Biologics License Application to the FDA for a subcutaneous induction regimen of Tremfya for adults with moderately to severely active ulcerative colitis based on positive Phase III ASTRO trial results.